(37 days)
None
Not Found
No
The summary describes a quantitative immunoassay for total thyroxine, which is a standard laboratory test method and does not mention any AI or ML components.
No
The device is intended for the quantitative determination of total thyroxine (T4) in human serum, which is a diagnostic purpose ("useful in the diagnosis and treatment of thyroid diseases") rather than a direct therapeutic intervention.
Yes
The Intended Use section states that the test is "useful in the diagnosis and treatment of thyroid diseases," indicating its role in identifying or characterizing a disease.
No
The summary describes an EIA (Enzyme Immunoassay) test, which is a laboratory diagnostic method involving chemical reagents and physical processes to measure substances in biological samples. This inherently involves hardware (reagents, plates, readers, etc.) and is not a software-only device.
Yes, based on the provided information, the BioCheck Total T4 EIA is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "quantitative determination of total thyroxine (T4) in human serum." This involves testing a biological sample (human serum) outside of the body (in vitro) to obtain diagnostic information (determining T4 levels for the diagnosis and treatment of thyroid diseases).
This aligns perfectly with the definition of an IVD.
N/A
Intended Use / Indications for Use
The BioCheck Total T4 EIA is intended for the quantitative determination of total thyroxine (T4) in human serum. This test is useful in the diagnosis and treatment of thyroid diseases.
Product codes
KLI
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Not Found
Key Metrics
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1700 Total thyroxine test system.
(a)
Identification. A total thyroxine test system is a device intended to measure total (free and protein bound) thyroxine (thyroid hormone) in serum and plasma. Measurements obtained by this device are used in the diagnosis and treatment of thyroid diseases.(b)
Classification. Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
2 399 JUN
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Biocheck, Inc. C/O Robin J. Hellen, M. S. Hellen Professional Services 9418 Lasaine Avenue Northridge, CA 91325
Re: K991432
Trade Name: BioCheck Total T4 Enzyme Immunoassay Test Kit Regulatory Class: II Product Code: KLI Dated: May 21, 1999 Received: May 25, 1999
Dear Ms. Hellen:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
Image /page/0/Picture/9 description: The image shows a circular logo for the Department of Health & Human Services (HHS) in the USA. The logo features the HHS symbol, which consists of three stylized human figures connected by flowing lines, representing the department's mission to protect the health of all Americans and provide essential human services. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged around the upper portion of the circle.
1
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Dutman
Steven I. Gutman, M.D, M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Statement for Indications for Use III.
| 510(k) Number (if known): | K991432 |
|---|---|
| Device Name: | BioCheck, Inc. Total T4 Enzyme Immunoassay Test Kit |
| Indications for Use: | The BioCheck Total T4 EIA is intended for the quantitative determination of total thyroxine (T4) in human serum. This test is useful in the diagnosis and treatment of thyroid diseases. |
(Division Sign-Off:
Division Dir.:
| 510(k) Number | K991432 |
|---|---|
| --------------- | --------- |
Concurrence of the CDRH, Office of Device Evaluation (ODE)
| Prescription Use: | |
|---|---|
| OR | |
| Over the Counter Use: | __________________ |
and the comments of the comments of the comments of the comments of the comments of the contribution of the contribution of the contribution of the contribution of the contri